

## 

(43) International Publication Date 25 January 2001 (25.01.2001)

**PCT** 

## (10) International Publication Number WO 01/05813 A1

(51) International Patent Classification<sup>7</sup>: A61K 38/08, A61P 31/10

(21) International Application Number:

C07K 7/06,

(74) Agents: MUSSER, Arlene, K. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(22) International Filing Date:

PCT/US00/15016

8 June 2000 (08.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/143,840

15 July 1999 (15.07.1999) US

- (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHEN, Shu, Hui [US/US]; 13256 Snow Owl Drive, Carmel, IN 46033 (US). RODRIGUEZ, Michael, John [US/US]; 7649 Gordonshire Court, Indianapolis, IN 46278 (US). SUN, Xicheng, David [CN/US]; 9929 Brightwater Drive, Noblesville, IN 46060 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,

DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

## Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PSEUDOMYCIN PRODRUGS

R'HN

(57) Abstract: A pseudomycin prodrug represented by structure (A) where R1 is an acyloxyalkylcarbamate linkage is described. The prodrug demonstrates antifungal activity with less adverse side effects.